GGrantIndex
← Leaderboards

John H Growdon

Massachusetts General Hospital

$11,829,523
Attributed
$11,829,523
Total exposure
12
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.7M · FY200513
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13

Funding mix

By agency

NIH$24,092,778 · 13

By mechanism

P50$20,731,452 · 5
M01$3,046,243 · 6
R21$274,523 · 1
R13$40,560 · 1

Top collaborators

No co-investigators on record.

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectClinical ResearchAlzheimer'S DiseaseBrain Disorder ChemotherapyHuman Therapy EvaluationDrug Screening /EvaluationClinical Trial Phase IDementiaParkinson'S DiseaseAntiparkinson DrugsLongitudinal Human StudyDrug Administration Rate /DurationPathologic ProcessResearch PersonnelNeuropsychologicalNeurologicCognitionFundingBrain Disorder DiagnosisEnrollmentPatient /Disease RegistryBrainNeuroimagingGenetic Counseling

Grant awards (70)

CLINICAL CORE$553,860
P50 · FY2013 · AG · contact PI
CLINICAL CORE$640,286
P50 · FY2012 · AG · contact PI
CLINICAL CORE$599,141
P50 · FY2011 · AG · contact PI
CLINICAL CORE$608,529
P50 · FY2010 · AG · contact PI
CLINICAL CORE$594,563
P50 · FY2009 · AG · contact PI
Core--Clinical and Training$595,388
P50 · FY2008 · NS · contact PI
CORE--CLINICAL GENETIC & NEUROIMAGING$453,454
P50 · FY2008 · AG · contact PI
Neuroimaging Biomarkers to Distinguish Lewy Body Diseases$127,302
R21 · FY2008 · NS · contact PI
Core--Clinical and Training$720,436
P50 · FY2007 · NS · contact PI
CORE--CLINICAL GENETIC & NEUROIMAGING$486,512
P50 · FY2007 · AG · contact PI
Neuroimaging Biomarkers to Distinguish Lewy Body Diseases$147,221
R21 · FY2007 · NS · contact PI
Core--Clinical and Training$612,504
P50 · FY2006 · NS · contact PI
CORE--CLINICAL GENETIC & NEUROIMAGING$320,599
P50 · FY2006 · AG · contact PI
Massachusetts Alzheimer's Disease Research Center$1,761,743
P50 · FY2005 · AG
Core--Clinical and Training$612,504
P50 · FY2005 · NS
CORE--CLINICAL GENETIC &NEUROIMAGING$312,490
P50 · FY2005 · AG
Massachusetts Alzheimer's Disease Research Center$38,501
P50 · FY2005 · AG
SIMVASTATIN TREATMENT FOR ALZHEIMER'S DISEASE$15,301
M01 · FY2005 · RR
Massachusetts Alzheimer's Disease Research Center$1,715,010
P50 · FY2004 · AG
Core--Clinical and Training$612,212
P50 · FY2004 · NS
CORE--CLINICAL GENETIC &NEUROIMAGING$304,614
P50 · FY2004 · AG
ADMINISTRATIVE CORE$163,806
P50 · FY2004 · AG
Massachusetts Alzheimer's Disease Research Center$138,642
P50 · FY2004 · AG
Massachusetts Alzheimer's Disease Research Center$43,667
P50 · FY2004 · AG
SIMVASTATIN TREATMENT FOR ALZHEIMER'S DISEASE$15,485
M01 · FY2004 · RR
EVALUATE EFF VITAMIN E &DONEPEZIL HCI (ARICEPT) TO DELAY MILD COGN IMPR TO AD$2,212
M01 · FY2004 · RR
Massachusetts Alzheimer's Disease Research Center$2,000
P50 · FY2004 · AG
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$2,121,363
P50 · FY2003 · AG
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$126,075
P50 · FY2003 · AG
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$2,082,600
P50 · FY2002 · AG
Vitamin E &Donepezil (ARICEPT) in Alzheimer's$200,768
M01 · FY2002 · RR
ENTACAPONE IN PATIENTS WITH PARKINSONS DISEASE$200,768
M01 · FY2002 · RR
ENTACAPONE IN PATIENTS WITH PARKINSONS DISEASE$200,768
M01 · FY2002 · RR
STUDY OF ESTROGEN REPLACEMENT IN PATIENTS WITH ALZHEIMER'S DISEASE$200,768
M01 · FY2002 · RR
STUDY OF ESTROGEN REPLACEMENT IN PATIENTS WITH ALZHEIMER'S DISEASE$200,768
M01 · FY2002 · RR
EFFECT OF AF102B OF AMYLOID PROCESSING IN ALZHEIMERS DISEASE$200,768
M01 · FY2002 · RR
EFFECT OF AF102B OF AMYLOID PROCESSING IN ALZHEIMERS DISEASE$200,768
M01 · FY2002 · RR
Earlier vs Later Levodopa in Parkinson's Disease$200,768
M01 · FY2002 · RR
Earlier vs Later Levodopa in Parkinson's Disease$200,768
M01 · FY2002 · RR
Vitamin E &Donepezil (ARICEPT) in Alzheimer's$200,768
M01 · FY2002 · RR
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$162,050
P50 · FY2002 · AG
CORE--CLINICAL$0
P50 · FY2002 · AG
CORE--CLINICAL$0
P50 · FY2002 · AG
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$2,028,958
P50 · FY2001 · AG
STUDY OF ESTROGEN REPLACEMENT IN PATIENTS WITH ALZHEIMER'S DISEASE$200,768
M01 · FY2001 · RR
ENTACAPONE IN PATIENTS WITH PARKINSONS DISEASE$200,768
M01 · FY2001 · RR
EFFECT OF AF102B OF AMYLOID PROCESSING IN ALZHEIMERS DISEASE$200,768
M01 · FY2001 · RR
Vitamin E &Donepezil (ARICEPT) in Alzheimer's$200,768
M01 · FY2001 · RR
Earlier vs Later Levodopa in Parkinson's Disease$200,768
M01 · FY2001 · RR
ENTACAPONE IN PATIENTS WITH PARKINSONS DISEASE$0
M01 · FY2001 · RR
CORE--CLINICAL$0
P50 · FY2001 · AG
Vitamin E &Donepezil (ARICEPT) in Alzheimer's$0
M01 · FY2001 · RR
Earlier vs Later Levodopa in Parkinson's Disease$0
M01 · FY2001 · RR
EFFECT OF AF102B OF AMYLOID PROCESSING IN ALZHEIMERS DISEASE$0
M01 · FY2001 · RR
STUDY OF ESTROGEN REPLACEMENT IN PATIENTS WITH ALZHEIMER'S DISEASE$0
M01 · FY2001 · RR
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$1,992,646
P50 · FY2000 · AG
CORE--CLINICAL$277,299
P50 · FY2000 · AG
MASSACHUSETTS ALZHEIMERS DISEASE RESEARCH CENTER$50,000
P50 · FY2000 · AG
INTERNATIONAL STUDY GROUP MEETING$40,560
R13 · FY2000 · AG
EFFECT OF AF102B OF AMYLOID PROCESSING IN ALZHEIMERS DISEASE$575
M01 · FY2000 · RR
STUDY OF ESTROGEN REPLACEMENT IN PATIENTS WITH ALZHEIMER'S DISEASE$575
M01 · FY2000 · RR
ENTACAPONE IN PATIENTS WITH PARKINSONS DISEASE$575
M01 · FY2000 · RR
STUDY OF ESTROGEN REPLACEMENT IN PATIENTS WITH ALZHEIMER'S DISEASE$0
M01 · FY2000 · RR
Vitamin E &Donepezil (ARICEPT) in Alzheimer's$0
M01 · FY2000 · RR
CORE--CLINICAL$0
P50 · FY2000 · AG
Vitamin E &Donepezil (ARICEPT) in Alzheimer's$0
M01 · FY2000 · RR
ENTACAPONE IN PATIENTS WITH PARKINSONS DISEASE$0
M01 · FY2000 · RR
Earlier vs Later Levodopa in Parkinson's Disease$0
M01 · FY2000 · RR
Earlier vs Later Levodopa in Parkinson's Disease$0
M01 · FY2000 · RR
EFFECT OF AF102B OF AMYLOID PROCESSING IN ALZHEIMERS DISEASE$0
M01 · FY2000 · RR